

January 23, 2024

**Acurx Pharmaceuticals**

# **Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024**

STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.

## **Presentation Details:**

Wednesday, January 31<sup>st</sup>, 2 pm ET and

Thursday, February 1<sup>st</sup> at 11:40 am ET

Interested parties can register to attend [here](#).

## **About Acurx Pharmaceuticals, Inc.**

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS<sup>®</sup>) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase III C (pol III C), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including *Clostridioides difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin resistant *Enterococcus* (VRE) and drug-resistant *Streptococcus pneumoniae* (DRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit [www.acurxpharma.com](http://www.acurxpharma.com)

## **Forward-Looking Statements**

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and

uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2022, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

**Investor Contact: Acurx Pharmaceuticals, Inc.**

David P. Luci

President & CEO

Tel: 917-533 1469

Email: [davidluci@acurxpharma.com](mailto:davidluci@acurxpharma.com)

 View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-microcap-conference-january-31-2024---february-1-2024-302041587.html>

SOURCE Acurx Pharmaceuticals, Inc.